noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

Financial Services

MFA - Managed Funds Association

MFA urges EU to strengthen competitiveness by supporting nonbank financing
Baker & McKenzie LLP

Baker McKenzie Advises HT5 on Successful Restructuring and Subsequent[...]
Mitsui Global Investment

Reunion Neuroscience Announces Positive Topline Results from RECONNECT[...]

Economy, Business and Finance

Mitsui Global Investment

06/23/2025 | Press release | Archived content

Servier to Acquire Exclusive Worldwide Rights of BioNova’s BN104, a potential best-in-class menin inhibitor

Today, Servier Pharmaceutics acquired the worldwide rights to BN104, a potential best-in-class precision therapy for AML and ALL, from BioNova Pharmaceuticals.

Mitsui Global Investment published this content on June 23, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 20, 2026 at 07:15 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format